Related Experiment Video

Updated: Feb 6, 2026

Absolute Quantitation of Inositol Pyrophosphates by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry
09:22

Absolute Quantitation of Inositol Pyrophosphates by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry

Published on: August 13, 2021

2.8K

Inositol 1,4,5-Trisphosphate Receptors in Hypertension

Ali H Eid1,2, Ahmed F El-Yazbi1,3, Fouad Zouein1

  • 1Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

Frontiers in Physiology
|August 11, 2018
PubMed

Insights

Chronic hypertension is linked to vascular aging and altered calcium signaling in vascular smooth muscle cells (VSMCs). Inositol trisphosphate receptors (IP3Rs) play a key role in hypertension development and VSMC changes.

Area of Science:

  • Cardiovascular Research
  • Vascular Biology
  • Hypertension Pathophysiology

Background:

  • Chronic hypertension is a leading global health issue, driven by complex genetic, environmental, and aging factors.
  • Vascular aging contributes to hypertension via endothelial dysfunction and altered vascular smooth muscle cell (VSMC) calcium (Ca2+) homeostasis, increasing myogenic tone.
  • Intracellular Ca2+ levels are regulated by extracellular influx (e.g., VGCCs, SOCs, CRACs) and intracellular release from the sarcoplasmic reticulum (SR) via IP3Rs and RyRs.

Purpose of the Study:

  • To review the role of inositol trisphosphate receptor (IP3R)-mediated Ca2+ release in hypertension.
  • To explore the connection between IP3R function, VSMC phenotypic switching, and vascular aging.
  • To identify potential therapeutic targets for hypertension management.

Main Methods:

  • Review of existing scientific literature on calcium signaling in hypertension and vascular aging.
  • Analysis of the role of IP3R isoforms in VSMC function and vascular remodeling.
  • Integration of evidence linking IP3R changes to hypertension development and aging.

Main Results:

  • IP3R-mediated Ca2+ release contributes to VSMC contraction, regulates VGCCs, and drives arterial structural remodeling in hypertension.
  • Hypertension involves VSMC phenotypic switching and altered cytoplasmic Ca2+ signaling, closely related to aging.
  • Changes in IP3R expression and function are implicated in hypertension, VSMC dedifferentiation, and vascular aging.

Conclusions:

  • IP3Rs are critical mediators in the development of hypertension, influencing VSMC behavior and vascular aging.
  • Targeting IP3R pathways may offer novel therapeutic strategies for managing hypertension.
  • Understanding the interplay between IP3Rs, calcium signaling, and vascular aging is crucial for future hypertension treatments.

Keywords:
Ca2+IP3RVSMCaginghypertension

More Related Videos

Extraction and Quantification of Soluble, Radiolabeled Inositol Polyphosphates from Different Plant Species using SAX-HPLC09:01

Extraction and Quantification of Soluble, Radiolabeled Inositol Polyphosphates from Different Plant Species using SAX-HPLC

Published on: June 26, 2020

7.6K
Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry08:07

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry

Published on: July 26, 2019

9.0K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
477
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
512
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
911
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
969
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
452